Candel Therapeutics(CADL) - 2024 Q1 - Quarterly Results

▪ Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CAN-2409 for the treatment of pancreatic cancer. ▪ Received Fast Track Designation from the FDA for CAN-3110 for the treatment of patients with rHGG to improve OS. ▪ Presented preclinical data at the AACR Annual Meeting unveiling the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce tertiary lymphoid structures (TLS), being developed as a novel therapeu ...